Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes

British Journal of Cancer

Volumn 110, Issue 2, 2014, Pages 375-383

  Peeters, D J E ^a,b   Van Dam, P J ^a   Van Den Eynden, G G M ^a   Rutten, A ^a   Wuyts, H ^a   Pouillon, L ^a   Peeters, M ^b   Pauwels, P ^b   Van Laere, S J ^a   Van Dam, P A ^a,b   Vermeulen, P B ^a   Dirix, L Y ^a  

^a Oncology Centre of Antwerp   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

CellSearch system; circulating tumour cells; immunohistochemical subtypes; metastatic breast cancer; prognostic significance

Indexed keywords

BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PERTUZUMAB; TRASTUZUMAB; CYTOTOXIC AGENT; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB EMTANSINE;

AGED; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL COUNT; CIRCULATING TUMOR CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; SYSTEMIC THERAPY; ADULT; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CORRELATION ANALYSIS; DIAGNOSTIC EQUIPMENT; HISTOPATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL COUNT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 84892921370     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.743     Document Type: Article

References (29)

1. Arpino G, Bardou VJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6: R149-R156.
2. Bidard F-C, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabières C, Janni W, Messina C, Paoletti C, Müller V, Hayes DF, Piccart M, Pierga J-Y (2013) Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev 32: 179-188.
3. Bidard F-C, Mathiot C, Degeorges A, Etienne-Grimaldi M-C, Delva R, Pivot X, Veyret C, Bergougnoux L, De Cremoux P, Milano G, Pierga J-Y (2010) Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 21: 1765-1771.
4. Botteri E, Sandri MT, Bagnardi V, Munzone E, Zorzino L, Rotmensz N, Casadio C, Cassatella MC, Esposito A, Curigliano G, Salvatici M, Verri E, Adamoli L, Goldhirsch A, Nolè F (2010) Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. Breast Cancer Res Treat 122: 211-217.
5. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen L.W.M.M., Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791.
6. Gainer SM, Lodhi AK, Bhattacharyya A, Krishnamurthy S, Kuerer HM, Lucci A (2012) Invasive lobular carcinoma predicts micrometastasis in breast cancer. J Surg Res 177: 93-96.
7. Giordano A, Egleston BL, Hajage D, Bland J, Hortobagyi GN, Reuben JM, Pierga J-Y, Cristofanilli M, Bidard F-C (2013) Establishment and validation of circulating tumor cell-based prognostic nomograms in firstline metastatic breast cancer patients. Clin Cancer Res 19: 1596-1602.
8. Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M (2012) Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 23: 1144-1150.
9. Giordano A, Giuliano M, Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, Placido S, Hess K, Cristofanilli M, Reuben JM (2011) Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Res Treat 129: 451-458.
10. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M (2011) Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 13: R67.
11. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J. Panel members (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747.
12. Kahan LS (2004) Medical devices; immunology and microbiology devices; classification of the immunomagnetic circulating cancer cell selection and enumeration system. Final rule. (Federal Register).
13. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23: 9067-9072.
14. Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensz N, Aurilio G, Curigliano G, Goldhirsch A, Nolè F (2012) Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Clin Breast Cancer 12: 340-346.
15. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
16. Pierga J-Y, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Dieras V, Rolland E, Mignot L, Mathiot C, Bidard F-C (2012) High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 23: 618-624.
17. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17: 343-346.
18. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens JWM, Gratama J-W, Sleijfer S, Foekens JA (2009) Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 101: 61-66.
19. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale A-L, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423.
20. Sotiriou C, Neo S-Y, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393-10398.
21. Soysal SD, Muenst S, Barbie T, Fleming T, Gao F, Spizzo G, Oertli D, Viehl CT, Obermann EC, Gillanders WE (2013) EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2\+, basal-like, and HER2 intrinsic subtypes of breast cancer. Br J Cancer 108: 1480-1487.
22. Swain SM, Kim S-B, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14: 461-471.
23. The Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
24. Van Der Auwera I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, Prové A, Maes H, Huget P, van Dam P, Vermeulen PB, Dirix LY (2010) Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer 102: 276-284.
25. Van Laere S, Van Der Auwera I, Van den Eynden G, Van Hummelen P, van Dam P, Van Marck E, Vermeulen PB, Dirix L (2007) Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis. Br J Cancer 97: 1165-1174.
26. Van Laere SJ, Elst H, Peeters D, Benoy I, Vermeulen PB, Dirix LY (2009) Re: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 101: 895-896.
27. Vincent-Salomon A, Caly M, De Rycke Y, Fréneaux P, Klijanienko J, Laé M, Viard F, Nos C, Bidard F-C, Alran S, Salmon R, Kirova Y, Pierga J-Y, Sigal-Zafrani B, Sastre-Garau X (2009) Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinoma. Eur J Cancer 45: 1979-1986.
28. Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K, Marmé F, Sohn C, Trumpp A, Rack B, Aktas B, Solomayer E-F, Müller V, Janni W, Schneeweiss A, Fehm TN (2012) The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 137: 503-510.
29. Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, Liu J, Pantel K (2012) Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 18: 5701-5710.